Literature DB >> 29337001

Antidepressant Treatment Duration in Pediatric Depressive and Anxiety Disorders: How Long is Long Enough?

Elizabeth E Hathaway1, John T Walkup2, Jeffrey R Strawn3.   

Abstract

Anxiety and depressive disorders are common in the pediatric primary care setting, and respond to both psychotherapeutic and psychopharmacologic treatment. However, there are limited data regarding the optimal treatment duration. This article systematically reviews guidelines and clinical trial data related to antidepressant treatment duration in pediatric patients with depressive and anxiety disorders. The extant literature suggests 9-12 months of antidepressant treatment for youth with major depressive disorder. For generalized, separation and social anxiety disorders, 6-9 months of antidepressant treatment may be sufficient, though many clinicians extend treatment to 12 months based on extrapolation of data from adults with anxiety disorders. Such extended treatment periods may decrease the risk of long-term morbidity and recurrence; however, the goal of treatment is ultimately remission, rather than duration of antidepressant pharmacotherapy. Moreover, while evidence-based guidelines represent a starting point, appropriate treatment duration varies and patient-specific response, psychological factors, and timing of discontinuation must be considered for individual pediatric patients.
Copyright © 2018 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29337001      PMCID: PMC5828899          DOI: 10.1016/j.cppeds.2017.12.002

Source DB:  PubMed          Journal:  Curr Probl Pediatr Adolesc Health Care        ISSN: 1538-3199


  46 in total

1.  Treatment of Resistant Depression in Adolescents (TORDIA): week 24 outcomes.

Authors:  Graham J Emslie; Taryn Mayes; Giovanna Porta; Benedetto Vitiello; Greg Clarke; Karen Dineen Wagner; Joan Rosenbaum Asarnow; Anthony Spirito; Boris Birmaher; Neal Ryan; Betsy Kennard; Lynn DeBar; James McCracken; Michael Strober; Matthew Onorato; Jamie Zelazny; Marty Keller; Satish Iyengar; David Brent
Journal:  Am J Psychiatry       Date:  2010-05-17       Impact factor: 18.112

2.  24- and 36-week outcomes for the Child/Adolescent Anxiety Multimodal Study (CAMS).

Authors:  John Piacentini; Shannon Bennett; Scott N Compton; Phillip C Kendall; Boris Birmaher; Anne Marie Albano; John March; Joel Sherrill; Dara Sakolsky; Golda Ginsburg; Moira Rynn; R Lindsey Bergman; Elizabeth Gosch; Bruce Waslick; Satish Iyengar; James McCracken; John Walkup
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2013-11-28       Impact factor: 8.829

Review 3.  Assessment and treatment of anxiety disorders in children and adolescents.

Authors:  Anna M Wehry; Katja Beesdo-Baum; Meghann M Hennelly; Sucheta D Connolly; Jeffrey R Strawn
Journal:  Curr Psychiatry Rep       Date:  2015-07       Impact factor: 5.285

4.  Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder.

Authors:  M A Rynn; L Siqueland; K Rickels
Journal:  Am J Psychiatry       Date:  2001-12       Impact factor: 18.112

5.  Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release.

Authors:  Karl Rickels; Bijan Etemad; Sarosh Khalid-Khan; Falk W Lohoff; Moira A Rynn; Robert J Gallop
Journal:  Arch Gen Psychiatry       Date:  2010-12

6.  A randomized, placebo-controlled study of duloxetine for the treatment of children and adolescents with generalized anxiety disorder.

Authors:  Jeffrey R Strawn; Apurva Prakash; Qi Zhang; Beth A Pangallo; Chad E Stroud; Na Cai; Robert L Findling
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2015-01-29       Impact factor: 8.829

7.  Acute time to response in the Treatment for Adolescents with Depression Study (TADS).

Authors:  Christopher Kratochvil; Graham Emslie; Susan Silva; Steve McNulty; John Walkup; John Curry; Mark Reinecke; Benedetto Vitiello; Paul Rohde; Nora Feeny; Charles Casat; Sanjeev Pathak; Elizabeth Weller; Diane May; Taryn Mayes; Michele Robins; John March
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2006-12       Impact factor: 8.829

8.  Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.

Authors:  John March; Susan Silva; Stephen Petrycki; John Curry; Karen Wells; John Fairbank; Barbara Burns; Marisa Domino; Steven McNulty; Benedetto Vitiello; Joanne Severe
Journal:  JAMA       Date:  2004-08-18       Impact factor: 56.272

9.  Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.

Authors:  David Brent; Graham Emslie; Greg Clarke; Karen Dineen Wagner; Joan Rosenbaum Asarnow; Marty Keller; Benedetto Vitiello; Louise Ritz; Satish Iyengar; Kaleab Abebe; Boris Birmaher; Neal Ryan; Betsy Kennard; Carroll Hughes; Lynn DeBar; James McCracken; Michael Strober; Robert Suddath; Anthony Spirito; Henrietta Leonard; Nadine Melhem; Giovanna Porta; Matthew Onorato; Jamie Zelazny
Journal:  JAMA       Date:  2008-02-27       Impact factor: 56.272

10.  Child/Adolescent Anxiety Multimodal Study (CAMS): rationale, design, and methods.

Authors:  Scott N Compton; John T Walkup; Anne Marie Albano; John C Piacentini; Boris Birmaher; Joel T Sherrill; Golda S Ginsburg; Moira A Rynn; James T McCracken; Bruce D Waslick; Satish Iyengar; Phillip C Kendall; John S March
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2010-01-05       Impact factor: 3.033

View more
  3 in total

Review 1.  Psychopharmacology in Pediatric Mixed Anxiety Disorder: An Evidence-based Review.

Authors:  Sadiq Naveed; Afshan Naz Amray; Nusrat Jahan; Fatima Bilal Moti-Wala; Muhammad Hassan Majeed
Journal:  Innov Clin Neurosci       Date:  2019-09-01

Review 2.  Psychopharmacology of Pediatric Anxiety Disorders: A Narrative Review.

Authors:  Afshan N Amray; Khurram Munir; Nusrat Jahan; Fatima B Motiwala; Sadiq Naveed
Journal:  Cureus       Date:  2019-08-26

3.  Cost-Benefit Analysis of an Intervention in Divorced Parents: Implications for Society, Public Administrations and Family Visitation Centers.

Authors:  Leire Alcaniz; Ana Martínez-Pampliega; Marta Herrero
Journal:  Int J Environ Res Public Health       Date:  2022-03-15       Impact factor: 3.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.